-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Nucleozin
Category | Influenza Virus |
CAS | 341001-38-5 |
Description | Nucleozin is a cell-permeable isoxazolylpiperazine, which targets influenza a nucleoprotein (NP) to inhibit influenza A H1N1, H3N2 and H5N1. |
Product Information
Synonyms | 1-(2-Chloro-4-nitrophenyl)-4-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-piperazine; [4-(2-Chloro-4-nitro-phenyl)-piperazin-1-yl]-(5-methyl-3-phenyl-isoxazol-4-yl)-methanone |
IUPAC Name | [4-(2-chloro-4-nitrophenyl)piperazin-1-yl]-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone |
Molecular Weight | 426.85 |
Molecular Formula | C21H19ClN4O4 |
Canonical SMILES | CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N3CCN(CC3)C4=C(C=C(C=C4)[N+](=O)[O-])Cl |
InChI | InChI=1S/C21H19ClN4O4/c1-14-19(20(23-30-14)15-5-3-2-4-6-15)21(27)25-11-9-24(10-12-25)18-8-7-16(26(28)29)13-17(18)22/h2-8,13H,9-12H2,1H3 |
InChIKey | OWXBJAPOSQSWAO-UHFFFAOYSA-N |
Boiling Point | 673.8°C at 760 mmHg |
Flash Point | 361.3°C |
Purity | ≥98% |
Density | 1.371 g/cm3 |
Solubility | Soluble in DMSO |
Appearance | Yellow powder |
Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
Storage | Store at -20 °C |
Complexity | 619 |
Exact Mass | 426.1094828 |
Index Of Refraction | 1.631 |
In Vitro | Nucleozin inhibits infection of MDCK cells by the viruses influenza A/WSN/33, H3N2 and Vietnam/1194/04 (H5N1) with an 50 of 0.069 μM, 0.16 μM and 0.33 μM in plaque reduction assay (PRA) , respectively, severely suppresses viral growth at 0.1 μM and totally inhibites virus production at 1 μM in multicycle growth assays. |
PSA | 95.40000 |
Target | Influenza Virus |
XLogP3-AA | 3.9 |